PMDS: Freeing Resources for Respiratory Focus

In a strategic move, PMD Device Solutions (PMDS) has completed the sale of the Coala Life Monitor to its inventor, Magnus Sörlander. This transaction, stemming from a strategic agreement established in May 2024, allows PMDS to focus on its core competencies in respiratory monitoring while Sörlander pursues new growth opportunities for the cardiac health tech. This strategic shift enables PMDS to deepen its leadership in digital healthcare, particularly in remote monitoring of chronic respiratory conditions.

The sale, totaling 1.6 MSEK plus additional royalties, signifies PMDS' commitment to leadership in digital healthcare. By divesting a non-core asset, PMDS retains ownership of its remote patient monitoring platform and US operations, allowing it to concentrate on delivering innovative solutions to healthcare providers worldwide. This strategic maneuver enables PMDS to lead in digital healthcare, particularly in remote monitoring of patients with chronic respiratory conditions, strengthening its potential for driving innovation and improving patient care.



Given its core investment values, PMDS' focus on respiratory monitoring aligns with the author's preference for 'boring but lucrative' investments. By concentrating on a stable market with predictable growth, PMDS avoids surprises and maintains consistent performance. This approach, coupled with strategic acquisitions and organic growth, positions PMDS well in the competitive medtech industry.



In conclusion, PMDS' completion of the Coala Life Monitor sale allows the company to deepen its focus on digital healthcare, particularly in the remote monitoring of patients with chronic respiratory conditions. With a leaner portfolio and enhanced innovation capabilities, PMDS is poised to maintain its competitive edge in the medtech industry, resonating with the author's investment preferences for stability, predictability, and consistent growth.